MX360634B - Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. - Google Patents

Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.

Info

Publication number
MX360634B
MX360634B MX2014013294A MX2014013294A MX360634B MX 360634 B MX360634 B MX 360634B MX 2014013294 A MX2014013294 A MX 2014013294A MX 2014013294 A MX2014013294 A MX 2014013294A MX 360634 B MX360634 B MX 360634B
Authority
MX
Mexico
Prior art keywords
ssao
substituted
diseases
haloallylamine
inhibitors
Prior art date
Application number
MX2014013294A
Other languages
English (en)
Other versions
MX2014013294A (es
Inventor
Deodhar Mandar
Dorothy Findlay Alison
Stuart Foot Jonathan
Jarolimek Wolfgang
Alexander Mcdonald Ian
Ivan Turner Craig
Robertson Alan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2014013294A publication Critical patent/MX2014013294A/es
Publication of MX360634B publication Critical patent/MX360634B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/26—Thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está relacionada con la preparación y uso farmacéutico de derivados de 3-haloalilamina sustituidos en la forma de inhibidores SSAO/VAP-1 que tienen la estructura de la fórmula (I), tal como se define en la especificación. La presente invención también se refiere a métodos para utilizar compuestos de la fórmula (I) o una sal farmacéuticamente aceptable o derivado del mismo, para el tratamiento de una variedad de indicaciones, por ejemplo, enfermedades inflamatorias, enfermedades oculares, enfermedades fibróticas, enfermedades inducidas por diabetes y cáncer.
MX2014013294A 2012-05-02 2013-04-05 Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. MX360634B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641814P 2012-05-02 2012-05-02
PCT/AU2013/000356 WO2013163675A1 (en) 2012-05-02 2013-04-05 Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Publications (2)

Publication Number Publication Date
MX2014013294A MX2014013294A (es) 2015-05-08
MX360634B true MX360634B (es) 2018-11-12

Family

ID=49514094

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013294A MX360634B (es) 2012-05-02 2013-04-05 Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
MX2018009129A MX377635B (es) 2012-05-02 2013-04-05 Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018009129A MX377635B (es) 2012-05-02 2013-04-05 Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos

Country Status (24)

Country Link
US (4) US9302986B2 (es)
EP (2) EP2844637B1 (es)
JP (3) JP6182595B2 (es)
KR (2) KR20200030126A (es)
CN (2) CN107266332B (es)
AU (2) AU2013255103B2 (es)
BR (1) BR112014027406B1 (es)
CA (2) CA2871793C (es)
CY (1) CY1120334T1 (es)
DK (1) DK2844637T5 (es)
ES (1) ES2668300T3 (es)
HR (1) HRP20180953T1 (es)
HU (1) HUE038437T2 (es)
LT (1) LT2844637T (es)
ME (1) ME03063B (es)
MX (2) MX360634B (es)
NO (1) NO2842608T3 (es)
PL (1) PL2844637T3 (es)
PT (1) PT2844637T (es)
RS (1) RS57086B1 (es)
SG (2) SG11201406948PA (es)
SI (1) SI2844637T1 (es)
TR (1) TR201807453T4 (es)
WO (1) WO2013163675A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2844637T (pt) * 2012-05-02 2018-04-17 Boehringer Ingelheim Int Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018076236A (ja) * 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
AU2016366635A1 (en) 2015-12-07 2018-06-21 Benevolentai Cambridge Limited VAP-1 inhibitors for treating pain
WO2017136870A1 (en) * 2016-02-12 2017-08-17 Pharmaxis Ltd. Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN108341752B (zh) * 2017-01-21 2022-12-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
NZ755847A (en) 2017-03-01 2021-12-24 Boehringer Ingelheim Int Transition metal-catalyzed protodecarboxylation of α-halo-acrylic acid derivatives
JP2020508996A (ja) * 2017-03-02 2020-03-26 ファーマクシス リミテッド リシルオキシダーゼのハロアリルアミンピラゾール誘導体阻害剤およびその使用
EP3617186A1 (en) * 2017-04-28 2020-03-04 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine derivative and use thereof
MX2019014201A (es) * 2017-05-31 2020-01-23 Boehringer Ingelheim Int Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
FI3626699T3 (fi) 2017-06-20 2023-08-15 Shandong Danhong Pharmaceutical Co Ltd Ssao:n estäjä
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN110914234B (zh) * 2017-08-04 2023-06-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
MX2021001347A (es) * 2018-08-03 2021-04-13 Pharmaxis Ltd Inhibidores derivados de haloalilamina sulfona de lisil oxidasas y sus usos.
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CA3114166A1 (en) * 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
CN113164454A (zh) * 2018-09-28 2021-07-23 奥克塞拉有限公司 Vap-1的抑制剂
CN113226296A (zh) * 2018-10-24 2021-08-06 梅塔科林公司 Ssao抑制剂及其用途
CN112955215B (zh) * 2018-10-29 2024-05-17 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
CN112955214B (zh) * 2018-10-29 2024-05-07 勃林格殷格翰国际有限公司 吡啶基磺酰胺衍生物、药物组合物及其用途
WO2020117987A1 (en) * 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
ES2981573T3 (es) 2018-12-20 2024-10-09 Shangdong Danhong Pharmaceutical Co Ltd Ruta de procedimiento del compuesto de fórmula (IV), forma cristalina y método de preparación para el mismo
SG11202107498VA (en) * 2019-01-11 2021-08-30 Nanjing Transthera Biosciences Co Ltd Haloallylamine compounds and application thereof
CN113748104B (zh) * 2019-05-20 2024-02-27 广东东阳光药业股份有限公司 抑制ssao/vap-1的异喹啉酮类化合物及其用途
CA3145738A1 (en) * 2019-07-25 2021-01-28 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
AU2020377093B2 (en) 2019-10-29 2026-02-26 Eccogene Inc. SSAO inhibitors and use thereof
WO2021102774A1 (zh) * 2019-11-28 2021-06-03 广东东阳光药业有限公司 一种作为ssao/vap-1抑制剂的胺类衍生物及其用途
PE20230997A1 (es) * 2020-03-25 2023-06-26 Terns Inc Tratamiento de trastornos respiratorios
CN111654920B (zh) * 2020-06-02 2022-03-11 重庆邮电大学 一种分布式能效子载波功率分配方法
US12428370B2 (en) 2020-06-26 2025-09-30 Syntara Limited Haloallylamine dual amine oxidase inhibitors
EP4204405A4 (en) 2020-08-25 2024-05-29 Eli Lilly and Company POLYMORPHS OF AN SSAO INHIBITOR
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
JP2025528475A (ja) * 2022-08-29 2025-08-28 シンタラ・リミテッド リシルオキシダーゼの新規選択的阻害剤
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2025107036A1 (en) * 2023-11-23 2025-05-30 Syntara Limited Dual inhibitors of amine oxidases and peroxidases, and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4454158A (en) 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ZA855101B (en) 1984-07-13 1986-05-28 Merrell Dow Pharma Fluoroallylaine derivatives
US4699928A (en) 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
US4650907A (en) 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
CA2556914A1 (en) 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US9161922B2 (en) 2005-07-01 2015-10-20 Case Western Reserve University Amine oxidase inhibitors
EP2004166A2 (en) 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
US8110562B2 (en) 2006-07-19 2012-02-07 University Of Tennessee Research Foundation Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US20100210697A1 (en) 2007-10-19 2010-08-19 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
WO2009061830A1 (en) 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
JP2011504485A (ja) * 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
PT2844637T (pt) * 2012-05-02 2018-04-17 Boehringer Ingelheim Int Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações

Also Published As

Publication number Publication date
HK1245237A1 (zh) 2018-08-24
PT2844637T (pt) 2018-04-17
CN104520268B (zh) 2017-05-24
KR20200030126A (ko) 2020-03-19
US9815782B2 (en) 2017-11-14
NO2842608T3 (es) 2018-07-21
US9302986B2 (en) 2016-04-05
ME03063B (me) 2019-01-20
BR112014027406B1 (pt) 2020-09-24
CN107266332A (zh) 2017-10-20
AU2013203655A1 (en) 2013-11-21
AU2013255103A1 (en) 2014-11-06
TR201807453T4 (tr) 2018-06-21
JP2015521167A (ja) 2015-07-27
CA2871793C (en) 2020-09-15
KR102089935B1 (ko) 2020-03-18
RS57086B1 (sr) 2018-06-29
HK1203477A1 (en) 2015-10-30
EP2844637B1 (en) 2018-03-28
KR20150014926A (ko) 2015-02-09
US20180086698A1 (en) 2018-03-29
EP3438087A1 (en) 2019-02-06
BR112014027406A2 (pt) 2017-06-27
CY1120334T1 (el) 2019-07-10
DK2844637T3 (en) 2018-04-23
PL2844637T3 (pl) 2018-09-28
SG10201707020TA (en) 2017-10-30
JP6182595B2 (ja) 2017-08-16
DK2844637T5 (en) 2018-08-13
US20190071396A1 (en) 2019-03-07
SG11201406948PA (en) 2014-11-27
CA2871793A1 (en) 2013-11-07
EP2844637A4 (en) 2015-12-09
AU2013203655B2 (en) 2017-02-02
HUE038437T2 (hu) 2018-10-29
CN104520268A (zh) 2015-04-15
MX2014013294A (es) 2015-05-08
US20160244406A1 (en) 2016-08-25
JP6602802B2 (ja) 2019-11-06
JP2017132767A (ja) 2017-08-03
JP2020019810A (ja) 2020-02-06
EP2844637A1 (en) 2015-03-11
US20150158813A1 (en) 2015-06-11
MX377635B (es) 2025-03-11
HRP20180953T1 (hr) 2018-07-27
CN107266332B (zh) 2020-07-24
US10160723B2 (en) 2018-12-25
WO2013163675A1 (en) 2013-11-07
ES2668300T3 (es) 2018-05-17
CA3086105A1 (en) 2013-11-07
SI2844637T1 (en) 2018-07-31
AU2013255103B2 (en) 2016-09-29
LT2844637T (lt) 2018-05-10

Similar Documents

Publication Publication Date Title
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
IN2014MN01755A (es)
AU2012214029A8 (en) Rorgammat inhibitors
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
MX2013012588A (es) Inhibidores de cinasa.
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
PH12016502355B1 (en) Pharmaceutical composition
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
IN2015DN01119A (es)
IN2015DN01151A (es)
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
IN2013DN02555A (es)
IN2015MN00045A (es)
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
NZ622953A (en) Novel soft rock inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

FG Grant or registration